| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | Dupixent (dupilumab) | Bronchial asthma | PDUFA | Ongoing | Subcutaneous | Respiratory |
| Regeneron Pharmaceuticals Inc. | EYLEA HD (aflibercept) - (PHOTON ext) | Diabetic macular edema (DME) | BLA Filing | Data Released | Intravitreal injection | Opthalmic |
| Regeneron Pharmaceuticals Inc. | EYLEA (aflibercept) Injection (16-week dose) | Diabetic retinopathy (DR) | BLA Filing | Withdrawn | Intravitreal | Opthalmic |
| Regeneron Pharmaceuticals Inc. | Ronapreve (REGEN-COV 2066) | COVID-19 (Anti-viral antibody) | BLA Filing | Trial Planned | Intravenous injection | COVID-19 |
| Regeneron Pharmaceuticals Inc. | C5 Combo (pozelimab and cemdisiran) - (NIMBLE) | Myasthenia gravis (MG) | NDA Filing | Ongoing | Subcutaneous | Neurology |
| Regeneron Pharmaceuticals Inc. | LIBTAYO (cemiplimab) | Cervical cancer | NDA Filing | Withdrawn | intravenous | Oncology |
| Regeneron Pharmaceuticals Inc. | LIBTAYO (cemiplimab) | Cervical cancer | NDA Filing | Withdrawn | intravenous | Oncology |
| Regeneron Pharmaceuticals Inc. | EYLEA (aflibercept) - (SIENNA) | Retinal vein occlusion | NDA Filing | Ongoing | Intravitreal | Opthalmic |